Flora Growth Corp. (FLGC) has released an update.
Flora Growth Corp., a global leader in consumer-packaged goods and pharmaceutical distribution, celebrates the DEA’s potential decision to downgrade cannabis to Schedule III, signifying lower abuse potential and recognized medical use. This move aligns with the company’s market presence in the U.S. and Germany, both prominent players in the burgeoning legal cannabis sector. Flora Growth’s CEO, Clifford Starke, expresses support for the change, anticipating increased accessibility and ongoing positive momentum for the cannabis industry.
For further insights into FLGC stock, check out TipRanks’ Stock Analysis page.
